237429-63-9

Upstream product

• 495-69-2 Hippuric Acid 
• 17626-40-3 4-cyano-1,2-phenylenediamine 

Downstream Products

• 237429-64-0 5-formyl-2-[(N-benzoyl)aminomethyl]benzimidazole 

Relevant academic research and scientific papers

2'-Substituted 5-phenylterbenzimidazoles as topoisomerase I poisons

5-Phenylterbenzimidazole (1) is active as a topoisomerase I poison (topo I) and is cytotoxic to human tumor cells. No cross-resistance was observed for 1 when it was evaluated against the camptothecin-resistant cell line, CPT-K5. Derivatives of 1 substituted at the 2'-position, however, did exhibit cross-resistance to this cell line. The basis for the resistance of this cell line towards CPT is that it possesses a mutant form of topo I. These results suggest that substituents at the 2'-position may be in proximity to the wild-type enzyme. Therefore, we hypothesized that terbenzimidazoles with 2'-substituents could be capable of interacting with the enzyme and thereby influence activity within this class of topo I poisons. 5-Phenylterbenzimidazoles with a hydroxy, hydroxymethyl, mercapto, amino, N-benzoylaminomethyl, chloro, and trifluoromethyl group at the 2'-position were synthesized. In addition, several 2'-ethyl-5-phenylterbenzimidazoles were prepared containing either a methoxy, hydroxy, amino, or N-acetylamino group at the 2-position of the ethyl side-chain. These 2'-substituted 5-phenylterbenzimidazoles were evaluated as topo I poisons and for cytotoxic activity. The presence of a strong electron-withdrawing group at the 2'-position, such as a chloro or trifluoromethyl group, did enhance both topo I poisoning activity and cytotoxicity. Studies on the relative DNA binding affinity of 1 to its 2'-amino and 2'-trifluoromethyl derivatives did exhibit a correlation with their relative differences in biological activity. Copyright (C) 2000 Elsevier Science Ltd.

Heterocyclic topoisomerase poisons

The invention provides a topoisomerase poison of formula I: wherein R1-R8 have any of the meanings defined in the specification, or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising a compound of formula I or a salt thereof, intermediates useful for preparing a compound of formula I, and therapeutic methods comprising administering a compound of formula I or a salt thereof.